Alexander Drilon, MD
Phase I findings from the LIBRETTO-001 study (NCT03157128) in patients with RET
-altered solid tumors showed signals of clinical activity with LOXO-292. The addition of a drug like this to the paradigm could help an underserved population of patients with cancer, said Alexander E. Drilon, MD.
At the 2018 ASCO Annual Meeting, Drilon reported an objective complete response rate of 77% (95% CI, 58%-90%) with the highly selection RET inhibitor for patients with RET
fusion–positive non–small cell lung cancer (NSCLC), and 45% for patients with RET
-mutated medullary thyroid cancer. Eighty-two patients had been treated with LOXO-292 across 7 cohorts by the April 2018 data cutoff.
... to read the full story